drugset / Trial / NCT05192395
A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers
RandomizedCrossoverOpen-labelTreatment
Summary
A Randomized, Open-label, Single Oral Dosing, Two-sequence, and Four-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of DWJ1525 and the Co-administration of DWP16001 and DWC202101 for Healthy Subjects in Fed and Fasted State
Timeline
- Start
- 2022-04-15
- Primary completion
- 2022-05-24
- Completion
- 2022-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DWC202101 | Unknown | — | Oral |
| Subject | DWJ1525 | Unknown | — | Oral |
| Subject | Enavogliflozin | Small molecule | — | Oral |
Indications
No indication recorded.